GBM Stock Overview
A biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Inovio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.80 |
| 52 Week High | US$12.14 |
| 52 Week Low | US$3.69 |
| Beta | 0.83 |
| 11 Month Change | -25.05% |
| 3 Month Change | -42.34% |
| 1 Year Change | -10.80% |
| 33 Year Change | -95.03% |
| 5 Year Change | -86.23% |
| Change since IPO | -88.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| GBM | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -17.6% | -0.7% | -0.02% |
| 1Y | -10.8% | -17.2% | 8.2% |
Return vs Industry: GBM exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: GBM underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| GBM volatility | |
|---|---|
| GBM Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GBM's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: GBM's weekly volatility has decreased from 14% to 8% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 127 | Jacqueline Shea | www.inovio.com |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Inovio Pharmaceuticals, Inc. Fundamentals Summary
| GBM fundamental statistics | |
|---|---|
| Market cap | €102.01m |
| Earnings (TTM) | -€108.39m |
| Revenue (TTM) | €195.34k |
522.2x
P/S Ratio-0.9x
P/E RatioIs GBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GBM income statement (TTM) | |
|---|---|
| Revenue | US$203.41k |
| Cost of Revenue | US$81.97m |
| Gross Profit | -US$81.77m |
| Other Expenses | US$31.11m |
| Earnings | -US$112.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.32 |
| Gross Margin | -40,198.50% |
| Net Profit Margin | -55,491.09% |
| Debt/Equity Ratio | 0% |
How did GBM perform over the long term?
See historical performance and comparison